A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
Trial Summary
What is the purpose of this trial?
This trial is testing IMC-002, a new drug, in adults with advanced or recurring cancers. Researchers aim to understand how the drug works in the body and its effects on cancer.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications, but you cannot take certain drugs within 28 days before starting the study treatment.
Research Team
HEUNG TAE KIM
Principal Investigator
ImmuneOncia Therapeutics Inc.
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive escalating doses of IMC-002 to assess safety and tolerability
Expansion Cohorts
Participants receive IMC-002 at the recommended Phase 2 dose to further evaluate safety
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- IMC-002
Find a Clinic Near You
Who Is Running the Clinical Trial?
ImmuneOncia Therapeutics Inc.
Lead Sponsor